Target- |
MechanismRNA interference |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Sequitur, Inc.
0 Patents (Medical) associated with Sequitur, Inc.
01 Jan 2004·Expert Review of Molecular Diagnostics
Expediting target identification and validation through RNAi
Author: Samarsky, Dmitry ; Datta, Merrilyn
01 Aug 2003·IDrugs : the investigational drugs journal
Beyond Genome 2003--RNA Interference. Silencing genes for tools and applications. 16-17 June 2003, San Diego, CA, USA.
01 Jul 2003·Nature Biotechnology
Letter
Author: Hough, Shelley R. ; Taylor, Margaret F. ; Woolf, Tod M. ; Burrier, Althea C. ; Wiederholt, Kristin A.
100 Deals associated with Sequitur, Inc.
100 Translational Medicine associated with Sequitur, Inc.